| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| J0178 |
Injection, aflibercept, 1 mg |
12,624 |
9,035 |
$10.50M |
| 92014 |
Ophthalmological services: medical examination and evaluation, comprehensive, established patient |
79,089 |
65,080 |
$4.74M |
| 67028 |
Intravitreal injection of a pharmacologic agent |
53,087 |
39,062 |
$2.68M |
| 92134 |
|
94,498 |
78,226 |
$2.17M |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
8,782 |
7,850 |
$990K |
| J0177 |
Injection, aflibercept hd, 1 mg |
1,077 |
611 |
$585K |
| 92004 |
Ophthalmological services: medical examination and evaluation, comprehensive, new patient |
3,436 |
3,270 |
$434K |
| J2778 |
Injection, ranibizumab, 0.1 mg |
572 |
519 |
$400K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
5,078 |
4,392 |
$361K |
| 92226 |
|
21,371 |
13,997 |
$327K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
6,805 |
5,666 |
$310K |
| 92012 |
Ophthalmological services: medical examination and evaluation, intermediate, established patient |
6,021 |
5,090 |
$286K |
| J9035 |
Injection, bevacizumab, 10 mg |
4,607 |
3,533 |
$257K |
| 92202 |
|
33,530 |
26,983 |
$246K |
| 92250 |
|
4,524 |
3,806 |
$188K |
| 66984 |
Extracapsular cataract removal with insertion of intraocular lens prosthesis |
557 |
346 |
$145K |
| 92201 |
|
6,519 |
5,315 |
$111K |
| 92015 |
Determination of refractive state |
8,113 |
7,507 |
$99K |
| 92060 |
|
1,517 |
1,435 |
$96K |
| 92225 |
|
4,042 |
2,172 |
$80K |
| 92235 |
|
406 |
402 |
$31K |
| 99244 |
Office or other outpatient consultation, moderate to high complexity |
124 |
124 |
$23K |
| J3590 |
Unclassified biologics |
288 |
84 |
$22K |
| J2777 |
Injection, faricimab-svoa, 0.1 mg |
46 |
24 |
$22K |
| 92136 |
|
952 |
728 |
$20K |
| 92083 |
|
433 |
359 |
$13K |
| 92340 |
Fitting of spectacles, except for aphakia; monofocal |
670 |
658 |
$13K |
| 92133 |
|
525 |
450 |
$11K |
| Q5128 |
Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg |
14 |
12 |
$7K |
| 92020 |
|
520 |
484 |
$6K |
| 99222 |
Initial hospital care, per day, moderate complexity |
26 |
26 |
$3K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
28 |
28 |
$3K |
| 99205 |
Prolong outpt/office vis |
14 |
13 |
$3K |
| 76512 |
|
18 |
12 |
$633.52 |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
14 |
14 |
$597.63 |
| J7999 |
Compounded drug, not otherwise classified |
321 |
180 |
$482.22 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
9,857 |
9,318 |
$370.34 |
| 4040F |
|
5,108 |
4,809 |
$45.97 |
| 1036F |
|
9,334 |
8,787 |
$0.00 |
| 4177F |
|
1,079 |
1,035 |
$0.00 |
| G9903 |
Patient screened for tobacco use and identified as a tobacco non-user |
3,656 |
3,442 |
$0.00 |
| G8397 |
Dilated macular or fundus exam performed, including documentation of the presence or absence of macular edema and level of severity of retinopathy |
2,787 |
2,564 |
$0.00 |
| G9902 |
Patient screened for tobacco use and identified as a tobacco user |
48 |
43 |
$0.00 |
| 2019F |
|
625 |
604 |
$0.00 |
| 2023F |
|
25 |
25 |
$0.00 |
| 2022F |
|
3,488 |
3,237 |
$0.00 |
| 2021F |
|
2,710 |
2,493 |
$0.00 |
| G8482 |
Influenza immunization administered or previously received |
1,540 |
1,431 |
$0.00 |
| 5010F |
|
2,798 |
2,573 |
$0.00 |
| G9974 |
Dilated macular exam performed, including documentation of the presence or absence of macular thickening or geographic atrophy or hemorrhage and the level of macular degeneration severity |
417 |
399 |
$0.00 |